I am scoring all articles independently, then surfacing the top candidates for Phase 3 ranking. Articles with triage scores ≤4 or clearly out-of-scope (e.g., PMID42623813 — food chemistry) are scored briefly. Full scoring is applied to all HIGH-priority and substantive STANDARD articles.

---

Full Scoring Table (Top & Selected Articles)

#	PMID	Title (Short)	Scientific Novelty	Clinical Relevance	Population Reach	Implementation Speed	Evidence Strength	OpenClaw Triage Score	Evidence Maturity (Confirmed/Revised)
1	42623891	SPARROW: Spatially Fractionated Induction RT in LA-NSCLC	7	6	7	3	5	10	Exploratory → Exploratory (protocol only)
2	42624531	TILT-123 + TIL therapy immune-cytokine signature in melanoma	8	7	5	4	5	9	Validated → Validated
3	42624759	Bridging Early Feasibility & Pivotal Trials (tricuspid valve)	4	5	5	4	3	9	Exploratory → Exploratory
4	42623679	Richter transformation: immunologic strategies review	7	7	4	3	3	8	Exploratory → Exploratory
5	42624429	FYI on MRI: Breast MRI decision support in Black/Latina women	5	7	6	4	3	8	Exploratory → Exploratory
6	42624248	Multiplex ctDNA ddPCR assay for lung cancer detection	7	7	8	5	5	8	Validated → Validated
7	42624181	pCR reliability as endpoint in rectal cancer (review)	4	6	5	3	3	8	Exploratory → Exploratory
8	42623169	AI for osteonecrosis femoral head (meta-analysis)	4	6	5	5	6	8	Potentially Practice-Changing → Validated
9	42622847	Stacking AI model for pituitary microadenoma MRI	6	6	5	5	5	8	Validated → Validated
10	42624527	Emerging trends in prostate cancer treatment (review)	3	5	6	2	2	8	Exploratory → Exploratory
11	42624432	Pathogen-mimicking nanovaccine for cellular immunity	5	3	4	2	2	8	Exploratory → Exploratory
12	42624721	Lp(a) & Stanford type A aortic dissection after ACS (MR)	6	7	6	5	5	8	Validated → Validated
13	42624590	KiSO-DP: Women's menopausal transition cohort protocol	4	5	6	3	3	8	Validated → Exploratory (protocol only)
14	42622964	Neoantigen-based immunotherapy in CRC (review)	6	6	7	2	2	8	Exploratory → Exploratory
15	42619596	Latent representations for rare disease longitudinal data	5	4	4	3	3	8	Exploratory → Exploratory
16	42619239	EMG guidance for epidural blood patch (coma, SIH case)	6	5	2	5	2	8	Exploratory → Exploratory
17	42618742	Novel KDM5A variant: neurodevelopmental rare disease	6	4	2	3	3	8	Exploratory → Exploratory
18	42624698	GIL+VEN+AZA real-world delivery in FLT3+ R/R AML	4	7	5	6	5	7	Validated → Validated
19	42624697	Real-world venetoclax first-line AML (single center)	3	7	6	6	5	7	Validated → Validated
20	42624629	Bilateral optic neuropathy in CLL (case report)	5	5	2	4	2	7	Exploratory → Exploratory
21	42624247	NGS prediction model for unexplained cytopenia	6	7	6	6	5	7	Validated → Validated
22	42624179	CAR-T-associated coagulopathy review (CARAC)	5	7	6	4	3	7	Exploratory → Exploratory
23	42623961	AML disease burden in elderly (1990–2021 epidemiology)	3	5	6	3	3	7	Exploratory → Exploratory
24	42624396	US gynecologic cancer disparities & specialist access	4	7	7	4	4	7	Exploratory → Exploratory
25	42624598	AI prediction of NAC response in gastric cancer (meta)	5	6	6	4	5	7	Potentially Practice-Changing → Validated
26	42622976	AI for perioperative anaesthetic complication prediction	4	6	7	3	3	7	Exploratory → Exploratory
27	42624675	ESMO Gynae Cancers Congress 2026 summary (editorial)	3	5	5	3	2	7	Exploratory → Exploratory
28	42624381	PD-1/PD-L1 in neurological/psychiatric disorders (review)	6	5	7	2	2	7	Exploratory → Exploratory
29	42624180	KDM4A epigenetic reprogramming in cancer (review)	5	4	5	2	2	7	Exploratory → Exploratory
30	42624177	CCT6B candidate biomarker in HCC	4	4	5	3	3	7	Validated → Exploratory (self-described as candidate only)
31	42624032	PHGDH inhibition + PD-1 blockade in CRC	7	5	6	3	3	7	Validated → Validated
32	42623869	Neoantigen vaccine + NRT cells in solid tumor (preclinical)	6	4	5	2	2	7	Exploratory → Exploratory
33	42624727	Evolocumab vs ezetimibe for coronary plaque regression (RCT)	5	7	7	5	6	7	Potentially Practice-Changing → Validated
34	42624726	Sitosterolemia as underrecognized cause of thrombocytopenia	7	8	4	6	5	7	Validated → Validated
35	42624673	Intraoperative MAP target meta-analysis ("Quanto?")	4	8	8	7	7	7	Potentially Practice-Changing → Potentially Practice-Changing
36	42624612	Semaglutide cognitive effects in psychiatric patients (n=13,007)	7	7	8	5	5	7	Potentially Practice-Changing → Validated
37	42624319	Long-term extreme temperature exposure & hypertension	5	6	8	3	4	7	Validated → Validated
38	42622925	Rare disease diagnostic delay & healthcare trust (Sweden)	3	6	5	4	3	7	Exploratory → Exploratory
39	42621621	Ketogenic diet + immunomodulation in Rasmussen's encephalitis	5	5	2	4	2	7	Exploratory → Exploratory
40	42624670	Pregnancy-associated ECLS: nationwide dual-cohort analysis	5	7	5	5	5	7	Validated → Validated
41	42624591	Nurse-led family intervention for PTSS in pediatric cancer	4	6	6	5	4	7	Potentially Practice-Changing → Exploratory (protocol)
42	42624433	¹⁷⁷Lu-DOTA-7ND for FAP-targeted theranostics (first-in-human)	7	5	5	3	3	7	Exploratory → Exploratory
43	42624347	Biomaterial factors in silicone breast implant pathology	3	4	5	3	2	6	Exploratory → Exploratory
44	42624251	Pan-cancer exposome-wide analysis of modifiable risk factors	5	5	8	3	3	6	Exploratory → Exploratory
45	42624206	Early feasibility studies in Europe (French review)	2	3	4	3	2	6	Exploratory → Exploratory
46	42624191	ddPCR/liquid biopsy in AML: review	4	6	5	4	2	6	Exploratory → Exploratory
47	42624059	Microbial source tracking in tropical water quality	2	1	3	2	2	6	Exploratory → Exploratory (off-topic)
48	42619494	vWF & TSLP in preschool wheezing/asthma risk	5	5	6	4	4	6	Validated → Validated
49	42619337	CBC + cell population data for dengue risk stratification	5	6	7	6	5	6	Validated → Validated
50	42624507	AI for single-view mammographic asymmetry classification	5	6	7	5	4	6	Validated → Validated
51	42624249	Haystack MRD ctDNA assay: analytical + clinical validation	7	7	7	5	5	6	Validated → Validated
52	42624022	Prostate cancer immunophenotyping in East Africa (review)	6	6	6	3	2	6	Exploratory → Exploratory
53	42624190	ML for EDTA-dependent pseudothrombocytopenia	4	5	5	5	3	6	Exploratory → Exploratory
54	42623975	Decentralized federated learning for orthopedic imaging	4	4	5	3	3	6	Exploratory → Exploratory
55	42623758	S100A8 as hub linking inflammation & synaptic deficits in SCZ	5	4	6	2	3	6	Exploratory → Exploratory
56	42623243	LLM safety evaluation in healthcare (systematic review)	4	5	8	3	3	6	Exploratory → Exploratory
57	42623896	SP5 regulates sunitinib resistance in RCC via VEGFA/AKT	5	5	5	3	3	6	Validated → Validated
58	42623785	FOXA1 as prognostic biomarker in HPV+ cervical SCC	5	5	6	3	3	6	Exploratory → Exploratory
59	42624250	COMP⁺ CAFs & CD8⁺ T-cell exclusion in CRC (stromal checkpoint)	6	5	6	3	3	6	Validated → Validated
60	42623870	Clostridium butyricum + butyrate enhance PD-1 therapy (preclinical)	4	3	5	1	2	6	Exploratory → Exploratory
61	42624784	GLP-1 agonists beyond diabetes (narrative review)	2	5	8	4	2	6	Exploratory → Exploratory
62	42624738	Sleep health disparities in women of color (Utah qualitative)	4	5	6	4	3	6	Exploratory → Exploratory
63	42624725	Serial Lp(a) measurements in pediatric patients	5	6	5	5	4	6	Validated → Validated
64	42624723	Cardiometabolic multimorbidity & non-steatotic liver disease	4	5	6	3	3	6	Exploratory → Exploratory
65	42624330	GLP-1/SGLT2/MBS utilization trends in T2D+obesity (2010–2024)	3	5	8	4	4	6	Validated → Validated
66	42624785	Next-generation family medicine: comprehensiveness framework	2	4	7	4	2	6	Exploratory → Exploratory
67	42618902	Digital self-help for healthy aging in urban India	3	4	7	3	2	6	Exploratory → Exploratory
68	42619857	ArchSpiral: iPad spiral tracing for rare disease motor eval (preprint)	5	4	3	5	4	6	Exploratory → Exploratory
69	42624762	Patient-prosthesis mismatch after surgical AVR (20yr registry)	4	6	6	4	4	6	Exploratory → Exploratory
70	42624749	CKM syndrome staging & pancreatic resection outcomes	4	6	5	5	4	6	Validated → Validated
71	42624724	Dietary ketogenic ratio & mortality in CKM syndrome	4	5	5	4	4	6	Validated → Validated
72	42624615	SIK inhibitor HG-9-91-01 in RA fibroblast-like synoviocytes	4	3	5	2	2	5	Exploratory → Exploratory
73	42623680	Cytoreductive therapy in MPN-associated splanchnic vein thrombosis	5	7	4	6	5	5	Validated → Validated
74	42621033	Monocyte distribution width for sepsis in UAE cohort	4	5	5	5	4	5	Validated → Validated
75	42624065	Sequencing technologies for influenza wastewater surveillance	4	2	4	2	2	5	Exploratory → Exploratory
76	42623983	Patient-safe radiological language (nocebo reduction)	3	4	7	4	2	5	Exploratory → Exploratory
77	42623348	3D interactive radiology reports & AI acceptance	3	4	6	3	2	5	Exploratory → Exploratory
78	42623108	Multimodal AI chatbots in oral/maxillofacial radiology	3	3	4	2	2	5	Exploratory → Exploratory
79	42622965	AI in pituitary medicine (endocrinologist perspective)	2	3	4	3	2	5	Exploratory → Exploratory
80	42622945	GPT-5 performance on JSOMR board exam	2	2	3	2	2	5	Exploratory → Exploratory
81	42624161	Physics-informed vascular characterization in ULM	4	3	4	2	2	5	Exploratory → Exploratory
82	42624114	Mouth-to-gut microbiome signatures for GI cancer diagnosis	7	5	7	3	4	5	Validated → Validated
83	42624331	Long-chain fatty acid metabolism & antitumor immunity (review)	4	3	5	2	2	5	Exploratory → Exploratory
84	42624300	CCT/TRiC & therapy-induced senescence in GBM (animal)	4	2	4	1	2	5	Exploratory → Exploratory
85	42624103	Melanoma→rhabdomyosarcoma plasticity under immunotherapy	6	3	4	1	2	5	Exploratory → Exploratory
86	42623115	Patient advocacy to patient-driven research (rare diseases)	3	3	4	4	2	5	Exploratory → Exploratory
87	42624461	DM+COPD mortality trends in US 1999–2023	3	4	6	3	2	5	Exploratory → Exploratory
88	42623813	Metal-phenolic networks from black carrot pomace (food chem)	1	1	1	1	1	4	Exploratory → Exploratory (off-topic)
89	42624573	LLMs as peer reviewers (radiology)	2	2	3	2	2	4	Exploratory → Exploratory
90	42623915	Curcumin anti-tumor effects via NRF1α/NRF2 (in vitro HCC)	3	2	4	1	1	4	Exploratory → Exploratory
91	42624074	Cuproptosis enters the cancer-immunity circuit (comment)	4	2	4	1	1	4	Exploratory → Exploratory
92	42624457	LTBP2/HIF-1α in vascular calcification (animal)	3	2	4	1	1	4	Exploratory → Exploratory
93	42624342	Deltamethrin + dapagliflozin on I(Na) in atrial myocytes	2	2	3	1	1	4	Exploratory → Exploratory
94	42624565	ChIPmentation for histone modifications in aging (animal methods)	2	1	2	1	1	4	Exploratory → Exploratory
95	42619988	Uromodulin T62P variant & kidney injury (preprint)	5	4	4	2	3	4	Exploratory → Exploratory
96	42624410	CRC screening strategies in PMS2 Lynch syndrome (title only)	3	3	4	2	1	3	Exploratory → Exploratory
97	42624151	J-START trial: adjunctive US breast screening (authors' reply)	2	3	6	2	2	3	Exploratory → Exploratory
98	42624150	J-START trial: adjunctive US breast screening (letter)	2	3	6	2	2	3	Exploratory → Exploratory
99	42624149	J-START trial: adjunctive US breast screening (letter)	2	3	6	2	2	3	Exploratory → Exploratory
100	42624148	J-START trial: adjunctive US breast screening (letter)	2	3	6	2	2	3	Exploratory → Exploratory
101	42623498	The Diagnostic Mirage: AI in clinical diagnosis (letter)	2	2	3	1	1	3	Exploratory → Exploratory
102	42624611	Gross morphological type in HCC on atezo+bev (title only)	3	4	5	2	1	3	Exploratory → Exploratory
103	42624424	Case for primordial cardiometabolic prevention (editorial)	2	3	7	3	1	3	Exploratory → Exploratory
104	42623707	FSHD mortality review – response letter	1	1	2	1	1	3	Exploratory → Exploratory
105	42619294	NMNAT2-related polyneuropathy (title only, case)	2	2	2	2	1	3	Exploratory → Exploratory

---

Key Quantitative Results, Limitations, and Equity Notes (Selected Articles)

Article 1 — SPARROW (PMID 42623891)

• Quantitative result: Protocol publication only; no outcome data yet. This is a phase I/II RCT studying spatially fractionated radiotherapy (SFRT) + standard chemoradiation ± immunotherapy in LA-NSCLC.
• Validation status: Not yet externally validated; trial ongoing (DRKS00037163).
• Main limitation: Abstract/protocol only — zero efficacy or safety results available.
• Equity: LA-NSCLC disproportionately affects smokers, lower SES populations, and rural patients with limited access to specialized radiotherapy centers. If effective, SFRT requires advanced equipment unavailable in LMICs.
• Evidence Maturity Revision: Exploratory (downgraded from "Potentially Practice-Changing" — this is a protocol, not an outcome study).

Article 2 — TILT-123 + TIL Therapy (PMID 42624531)

• Quantitative result: Phase I cohort; immune-cytokine signatures correlate with survival. Mechanistic insights into IL-2-free TIL therapy. No RCT efficacy comparison reported.
• Validation status: Phase I, single-arm, no external replication.
• Main limitation: Small Phase I cohort; correlative; no survival endpoint powered for efficacy.
• Equity: Metastatic melanoma disproportionately affects lighter-skinned populations; however, checkpoint-resistant melanoma has high unmet need globally. IL-2-free protocol could reduce toxicity barriers in frail patients.
• Evidence Maturity: Validated (biomarker discovery in human trial; not practice-changing yet).

Article 3 — Bridging EFS & Pivotal Trials (PMID 42624759)

• Quantitative result: Regulatory review; no original clinical data.
• Main limitation: Review/opinion piece; highly limited generalizability.
• Evidence Maturity Revision: Exploratory (confirmed).

Article 34 — Sitosterolemia & Thrombocytopenia (PMID 42624726)

• Quantitative result: Targeted screening identified sitosterolemia in patients with chronic thrombocytopenia misdiagnosed as ITP; early treatment reverses hematologic findings.
• Main limitation: Retrospective, single-center design; small sample implied.
• Equity: Rare disease often missed due to phenotypic overlap with ITP; underserved populations with limited access to metabolic workup are at greatest risk of diagnostic delay.

Article 35 — Intraoperative Blood Pressure Targets (PMID 42624673)

• Quantitative result: Meta-analysis of 9 RCTs, n=14,658 patients. MAP ≥65 mmHg equally safe as higher targets; no reduction in organ injury or mortality with higher pressure targeting.
• Main limitation: Editorial commentary on meta-analysis; abstract only for the underlying study.
• Evidence Maturity: Potentially Practice-Changing (confirmed — large meta-analysis with clear null result).
• Equity: Applies broadly to surgical patients globally; important for lower-resource settings where aggressive hemodynamic management adds cost and complexity.

Article 36 — Semaglutide & Cognition in Psychiatric Patients (PMID 42624612)

• Quantitative result: Retrospective cohort, n=13,007; semaglutide associated with reduction in cognitive signs/symptoms in patients with psychiatric diagnoses.
• Main limitation: Retrospective, indication bias (healthier patients more likely prescribed semaglutide), confounding by comorbidities; causality unproven.
• Evidence Maturity: Validated (large real-world cohort with meaningful signal; needs RCT confirmation).
• Equity: Psychiatric populations are chronically underserved in metabolic healthcare; access to GLP-1 agonists is uneven across SES strata.

Article 51 — Haystack MRD Assay (PMID 42624249)

• Quantitative result: ctDNA detection highly concordant with orthogonal method (R stated but truncated in abstract). Analytical validation across tumor types.
• Main limitation: Observational validation only; no prospective clinical outcome data linked to MRD detection.
• Evidence Maturity: Validated (analytical validation confirmed; clinical utility validation pending).

Article 73 — Cytoreductive Therapy in MPN-SVT (PMID 42623680)

• Quantitative result: Cytoreductive therapy associated with reduced recurrent SVT in MPN; prior small studies were underpowered.
• Main limitation: Observational, multicenter; treatment switching introduces confounding.
• Evidence Maturity: Validated (confirmed — largest dataset to date on this question).

---

Conflict Note

No direct contradictions across articles in this batch. The batch does contain several articles on similar topics (e.g., multiple Lp(a) articles, four J-START letters) that are complementary rather than conflicting. The Quanto? editorial (PMID 42624673) directly summarizes a meta-analysis that is not itself in the batch.

---

Top 15 Ranked Articles

Composite Impact Score = (Clinical Relevance × 0.30) + (Population Reach × 0.25) + (Scientific Novelty × 0.20) + (Implementation Speed × 0.15) + (Evidence Strength × 0.10)

Rank	PMID	Short Title	Flag	Impact Score	Clin Rel (30%)	Pop Reach (25%)	Sci Nov (20%)	Impl Speed (15%)	Evid Str (10%)	OpenClaw Score	Study Design	Evidence Maturity
🥇 1	42624673	Intraoperative MAP targets — meta-analysis ("Quanto?")	⚪	6.80	8	8	4	7	7	7	Meta-analysis (editorial)	Potentially Practice-Changing
🥈 2	42624612	Semaglutide cognitive effects in psychiatric patients (n=13,007)	⚪	6.75	7	8	7	5	5	7	Retrospective cohort	Validated
🥉 3	42624248	Multiplex ctDNA ddPCR assay for lung cancer detection	🔴	6.55	7	8	7	5	5	8	Cohort/Observational	Validated
4	42624726	Sitosterolemia: underrecognized cause of thrombocytopenia	⚪	6.30	8	4	7	6	5	7	Cohort/Observational	Validated
5	42624531	TILT-123 + TIL therapy: immune-cytokine survival signature	⚪	6.10	7	5	8	4	5	9	Phase I cohort	Validated
6	42624721	Lp(a) & type A aortic dissection after ACS (MR analysis)	⚪	6.05	7	6	6	5	5	8	Cohort + Mendelian randomization	Validated
7	42624247	NGS prediction model for unexplained cytopenia	🟢	5.95	7	6	6	6	5	7	Cohort/Observational	Validated
8	42624396	US gynecologic cancer disparities & specialist access	🔴	5.85	7	7	4	4	4	7	Observational	Exploratory
9	42624249	Haystack MRD ctDNA assay: analytical + clinical validation	🔴	5.80	7	7	7	5	5	6	Cohort/Observational	Validated
10	42623679	Richter transformation: immunologic strategies beyond chemoimmunotherapy	🟠	5.60	7	4	7	3	3	8	Review	Exploratory
11	42623891	SPARROW: Spatially Fractionated RT in LA-NSCLC (protocol)	🟠	5.55	6	7	7	3	5	10	RCT protocol	Exploratory
12	42624179	CAR-T-associated coagulopathy (CARAC): review	🟠	5.45	7	6	5	4	3	7	Review	Exploratory
13	42624429	FYI on MRI: Breast MRI decision support in Black/Latina women	🔴🟡	5.45	7	6	5	4	3	8	RCT protocol	Exploratory
14	42623169	AI meta-analysis for osteonecrosis femoral head diagnosis	🟢	5.35	6	5	4	5	6	8	Meta-analysis	Validated
15	42624319	Extreme temperature exposure & hypertension risk (China cohort)	⚪	5.35	6	8	5	3	4	7	Cohort/Observational	Validated

---

Rank Justifications

Rank 1 — Quanto? Sessler, Br J Anaesth (PMID 42624673) This editorial synthesizes a meta-analysis of 9 RCTs in nearly 15,000 surgical patients, establishing that intraoperative mean arterial pressures ≥65 mmHg are safe even in high-risk elderly patients, and that higher pressure targets provide no additional organ protection. The evidence strength is exceptional for this domain (9 RCTs, n=14,658), and the clinical relevance is immediately actionable: anesthesiologists worldwide can safely de-escalate hemodynamic interventions, reducing vasopressor exposure, cost, and potential harm. Implementation speed is fast — this changes practice guidance without requiring new drugs, devices, or regulatory approval. Population reach is enormous given the global surgical volume. OpenClaw's triage score (7) underweighted this because the record is an editorial, but the underlying evidence it synthesizes is high-quality.

Why it matters: If confirmed at practice level, this frees anesthesiologists from aggressive hemodynamic targeting in millions of surgeries annually, reducing unnecessary vasopressor use with no mortality cost.

---

Rank 2 — Semaglutide cognition in psychiatric patients (PMID 42624612) A retrospective cohort of 13,007 patients with psychiatric diagnoses found semaglutide associated with reduced cognitive signs and symptoms — a novel and clinically meaningful signal in a deeply underserved population. GLP-1 agonists are already prescribed at scale; this suggests a pleiotropic cognitive benefit that could reshape prescribing in psychiatric settings. The Evidence Strength is moderate (retrospective, indication bias likely) but the sample size and novelty justify ranking. Psychiatric populations face major treatment gaps and unequal access to cardiometabolic drugs.

Why it matters: If replicated in RCTs, semaglutide could become one of the first agents to simultaneously address metabolic and cognitive deficits in psychiatric patients — a dual-benefit with massive unmet need.

---

Rank 3 — Multiplex ctDNA assay for lung cancer detection (PMID 42624248) A multiplex ddPCR ctDNA assay tested as a complement to LDCT lung cancer screening, addressing LDCT's known limitations of high false-positive rates and limited adherence. Lung cancer is the leading cause of cancer mortality worldwide, making any improvement in early detection of enormous population impact. This observational study provides preliminary validation; implementation could be relatively near-term given regulatory precedents for liquid biopsy in oncology.

Why it matters: A blood-based adjunct to lung cancer screening could meaningfully reduce LDCT false-positive rates and extend access in settings where CT infrastructure is limited.

---

Rank 4 — Sitosterolemia & thrombocytopenia (PMID 42624726) Highlights a treatable rare genetic disorder (sitosterolemia) commonly misdiagnosed as ITP, leading to years of inappropriate immunosuppression. Early diagnosis leads to dietary restriction and/or ezetimibe therapy with reversal of hematologic findings. Relative to its rare disease population, this has a high Clinical Relevance score (8/10) because correct diagnosis is immediately implementable, avoids harmful ITP-directed therapy, and eliminates long-term cardiovascular risk. Equity concern: sitosterolemia is more prevalent in populations with limited access to specialized metabolic workup.

Why it matters: Recognizing this diagnosis converts patients from lifelong inappropriate treatment to a correctable, manageable condition.

---

Rank 5 — TILT-123 + TIL therapy (PMID 42624531) A Phase I study showing immune-cytokine signatures predict survival in patients treated with oncolytic adenovirus TILT-123 + adoptive TIL therapy without high-dose IL-2, addressing a key toxicity bottleneck. The scientific novelty is high — eliminating IL-2 post-conditioning while maintaining antitumor efficacy would be a significant advance. The biomarker signature also provides a path to patient selection. Limitation: Phase I, small cohort, no efficacy comparison arm.

Why it matters: IL-2-free TIL therapy could extend adoptive cell therapy to patients currently excluded due to toxicity, particularly older or frail patients with checkpoint-resistant melanoma.

---

Ranks 6–15 are summarized above in the table. Notable highlights:

• Rank 6 (Lp[a] + aortic dissection after ACS): Mendelian randomization adds causal inference to an important cardiovascular risk question
• Rank 7 (NGS model for cytopenia): Near-term implementable diagnostic tool to reduce unnecessary myeloid NGS ordering
• Rank 8 (Gynecologic cancer disparities): Important equity data with actionable policy implications for a large underserved population
• Rank 9 (Haystack MRD assay): Strong analytical validation of a broad-use ctDNA MRD platform

---

PHASE 4 — Deep Dives

Per user instructions: Deep dive articles: [1, 2, 3]

---

[HOOK] Locally advanced lung cancer — cancer that has grown too far to cut out, but hasn't spread to distant organs — is one of medicine's most stubborn problems. More than half of patients experience locoregional failure after the best available treatment. Decades of attempts to simply crank up the radiation dose have failed, causing more harm without improving survival. A new clinical trial is betting that the pattern of radiation, not just the amount, could finally change the math.

[THE DISCOVERY] The SPARROW trial, registered in Germany and published as a protocol in Clinical Lung Cancer, is testing a technique called spatially fractionated radiotherapy (SFRT) as an induction strategy — delivered before the standard chemoradiation — in patients with inoperable locally advanced non-small-cell lung cancer. Instead of bathing the tumor in a uniform dose, SFRT delivers high-dose "peaks" and low-dose "valleys" across the tumor volume in a deliberate spatial pattern. The idea is that this kills highly resistant cancer cells in the peaks while triggering a systemic immune response through the valleys — potentially working with the immune system rather than just burning tissue.

Think of it like aerating a lawn before fertilizing: the pattern creates conditions for better uptake throughout.

[THE SCIENCE BEHIND IT] SPARROW is a multicenter, randomized, open-label seamless Phase I/II trial, which means it will first find the safe dose of SFRT (Phase I) and then test whether it improves outcomes over standard chemoradiation plus consolidation immunotherapy (Phase II), without stopping the trial in between. This seamless design is scientifically elegant — it accelerates the path from dose-finding to efficacy testing. The trial also incorporates biomarker correlative studies, including genomic profiling, which means it's built to understand why SFRT might work, not just whether it does. The major limitation is significant: this paper reports a protocol only. There are no outcome data yet, no safety signals, no efficacy results. We are at the starting gate.

[WHO THIS HELPS] The primary population is patients with inoperable stage III non-small-cell lung cancer — a group that represents roughly one-third of all newly diagnosed lung cancers. These patients currently face a median overall survival of less than 25 months even with modern chemoradiation plus durvalumab. Patients who cannot tolerate intensive chemoradiation or who have bulky tumors with poor prognostic features may particularly benefit if SFRT can remodel the tumor microenvironment before systemic therapy begins.

[THE REAL-WORLD IMPACT] If SFRT proves effective, implementation requires access to advanced radiotherapy planning systems capable of delivering non-uniform spatial dose patterns — technology available at major cancer centers but not universally accessible in lower-resource or rural settings. Workflows would need to incorporate an induction RT phase before chemoradiation, adding complexity. On the upside, SFRT does not add a new drug and may reduce the total radiation burden on normal tissue, potentially lowering toxicity. The combination with immunotherapy means a successful result would slot into an existing treatment paradigm rather than requiring a complete redesign.

[WHAT WE STILL DON'T KNOW] Everything. This is a protocol. We do not know whether SFRT is safe in this context, whether it improves response rates, whether the immune activation hypothesis holds in human lung tumors, or which patients are most likely to benefit. The trial may also be underpowered for definitive survival endpoints if Phase II enrollment is limited.

[LIKELIHOOD OF MAKING A DIFFERENCE]

• Scientific Confidence: Moderate — the biological rationale is sound and supported by preclinical and early clinical data, but clinical benefit in LA-NSCLC has not been demonstrated.
• Translation Speed: 5–10 years — this trial needs to complete enrollment, generate Phase II data, and ideally be confirmed in a Phase III study before it would change standard guidelines.
• Barrier Analysis:
  • Regulatory: Requires Phase III data for label-level adoption
  • Infrastructure: Specialized radiotherapy platforms required; equity gap in access
  • Reimbursement: SFRT techniques may face coding and coverage challenges in some systems
  • Awareness: Protocol publication itself builds the field; no immediate action required of clinicians

[CALL TO ACTION / CLOSING] The SPARROW trial won't give us answers today, but it asks exactly the right question: can we use radiation more intelligently, not just more aggressively, to help the immune system finish the job? Watch this space — the science is there, and the trial design is right.

---

[HOOK] Metastatic melanoma that has stopped responding to checkpoint immunotherapy is one of oncology's bleakest scenarios. For the small number of patients who reach adoptive TIL therapy — a treatment where their own tumor-infiltrating lymphocytes are grown and reinfused — there's hope, but the treatment carries serious toxicities from chemotherapy preconditioning and high-dose interleukin-2 that can make it inaccessible for many. A Finnish-Danish collaboration is now asking: what if we could make TIL therapy work without the most dangerous parts?

[THE DISCOVERY] The TUNINTIL trial tested a genetically engineered oncolytic adenovirus called TILT-123 — or igrelimogene litadenorepvec — combined with adoptive TIL therapy, but without standard lymphodepleting chemotherapy or high-dose IL-2 post-conditioning. The new paper in the Journal for ImmunoTherapy of Cancer goes further: it identifies a specific immune-cytokine signature in patients' blood that predicts who survived longer. In plain terms, researchers found that early patterns in the immune system's response — specific combinations of cytokines — told them, before outcomes were known, which patients would benefit most from this treatment.

[THE SCIENCE BEHIND IT] This is a Phase I cohort study embedded within the TUNINTIL trial (NCT04217473), which enrolled patients with metastatic melanoma who had already failed checkpoint inhibitors. Researchers analyzed cytokine and immune cell profiles longitudinally and identified signatures that correlated with survival. The biological logic is that TILT-123 delivers two immune-stimulating cytokines directly into the tumor microenvironment, potentially doing what IL-2 infusions tried to do systemically — with far less toxicity. The study design is inherently exploratory: Phase I means safety and dose-finding, not efficacy comparison. The sample size is small, and survival correlations are hypothesis-generating, not confirmatory. No randomized control arm exists. External validation is needed before these cytokine signatures can be used clinically.

[WHO THIS HELPS] Specifically: patients with advanced melanoma who have progressed on PD-1/PD-L1 checkpoint inhibitors and who might be eligible for TIL therapy but currently excluded due to age, organ function, or inability to tolerate IL-2 toxicity. More broadly, this approach — using an oncolytic virus to create a tumor microenvironment permissive to adoptive T-cell therapy — is a platform that could be adapted to other solid tumor types in future trials.

[THE REAL-WORLD IMPACT] If the IL-2-free approach is confirmed to maintain efficacy while reducing toxicity, TIL therapy's eligibility criteria could meaningfully expand. Currently, only a fraction of patients who might benefit from TIL therapy actually receive it, partly because high-dose IL-2 requires ICU-level monitoring. Removing that requirement — while retaining antitumor efficacy through viral immune priming — could democratize access. The cytokine signature biomarker, if validated, could also allow earlier identification of non-responders, sparing them unnecessary treatment. Practically, TILT-123 requires specialized manufacturing and regulated delivery, so implementation remains complex.

[WHAT WE STILL DON'T KNOW] The fundamental unknown is whether IL-2-free TIL + TILT-123 achieves comparable survival outcomes to standard TIL therapy in a properly powered comparison trial. The cytokine signatures need prospective validation in independent cohorts. We don't know the optimal patient selection criteria, the ideal virus dose, or how durable responses are. Phase I data, by design, cannot answer these questions.

[LIKELIHOOD OF MAKING A DIFFERENCE]

• Scientific Confidence: Moderate — the mechanistic rationale is strong, Phase I safety signals are encouraging, and the biomarker identification is a meaningful step. But survival data in a small, uncontrolled cohort is preliminary.
• Translation Speed: 5–10 years — a Phase II/III trial comparing IL-2-free to standard TIL therapy will be necessary.
• Barrier Analysis:
  • Regulatory: Oncolytic viral therapy requires separate regulatory review; complex combination product pathway
  • Manufacturing: Both TIL and adenoviral products require sophisticated GMP manufacturing
  • Cost: Personalized cell therapy is inherently expensive; access equity is a major concern
  • Reimbursement: TIL therapy (lifileucel) recently approved in the US; TILT-123 combination would require separate approval
  • Equity: These therapies remain concentrated in academic centers in high-income countries; global equity gap is significant

[CALL TO ACTION / CLOSING] The era of combination immunotherapy — teaching the tumor microenvironment to welcome its own destruction — is just beginning. TILT-123 plus TIL therapy isn't ready for the clinic yet, but it offers a genuinely new lever: replacing systemic toxicity with targeted viral priming, and pairing it with a biomarker that might tell us in advance who will win.

---

[HOOK] For decades, tricuspid valve disease — leaky valves on the right side of the heart — was largely left untreated because surgery was too risky for the frail, elderly patients who most commonly have it. Catheter-based fixes changed that, but getting a promising device from "it works in the lab" to "it's approved and used everywhere" is a regulatory odyssey that can take a decade. A new review in Clinical Therapeutics examines how the rules for this journey are changing on both sides of the Atlantic, and what that means for patients waiting for options.

[THE DISCOVERY] This review, identified as an unsolicited find by the triage system, synthesizes how Early Feasibility Studies (EFS) — the first-in-human stages of medical device development — work in practice for high-risk cardiovascular devices, specifically transcatheter tricuspid valve interventions (TTVI). The key finding is that the US has a relatively mature EFS framework through the FDA, while Europe is now developing analogous structured pathways (HEU-EFS initiative and MDCG 2025-9 guidance). The authors describe a trend toward transatlantic convergence — meaning devices can potentially be developed and tested in parallel across both regulatory environments, speeding time to availability for patients.

[THE SCIENCE BEHIND IT] This is a narrative review — not an original clinical study — and should be read as a regulatory and methodological synthesis. It draws on real-world case studies from TTVI development to illustrate how early feasibility data informs device iteration before large-scale pivotal trials. The value here is primarily for device developers, regulatory professionals, and clinicians involved in trial design. The evidence strength is low by conventional standards because no primary data are generated. The review's credibility rests on the authors' expertise and the quality of the regulatory documents cited, which we cannot fully evaluate from the abstract alone.

[WHO THIS HELPS] Directly: patients with tricuspid regurgitation — a condition affecting an estimated 1.6 million Americans with moderate-to-severe disease and vastly more globally who are currently undertreated because surgical options are too risky. Indirectly: patients with any high-risk cardiovascular condition where novel devices are in development. The regulatory harmonization described, if implemented, could shorten device development timelines across a range of conditions including mitral valve disease, heart failure devices, and structural heart interventions.

[THE REAL-WORLD IMPACT] Regulatory convergence between the US and EU is genuinely consequential. Currently, devices often navigate sequential regulatory pathways, duplicating studies and delaying access. If early feasibility frameworks are harmonized, the same first-in-human data could satisfy both the FDA and European regulators, potentially cutting years off approval timelines. For tricuspid valve patients specifically, this means faster access to catheter-based repair options that currently exist in a regulatory gray zone — promising in trials, but not yet widely approved. For health systems, it also means more transparent data requirements, potentially improving post-market surveillance.

[WHAT WE STILL DON'T KNOW] Whether the EU pathways described will be adopted uniformly across member states, and whether they will truly harmonize with US FDA expectations in practice, remains to be demonstrated. Regulatory convergence is aspirational; implementation varies by country, agency culture, and political environment. The review does not provide data on whether the proposed frameworks have already accelerated any specific device's development. The clinical outcomes of TTVI devices themselves — durability, mortality benefit, quality-of-life improvement — are still being established in ongoing pivotal trials.

[LIKELIHOOD OF MAKING A DIFFERENCE]

• Scientific Confidence: Low-to-Moderate — this is regulatory analysis, not clinical evidence. The framework described is plausible and well-grounded, but implementation is uncertain.
• Translation Speed: 5–10 years — regulatory harmonization is slow; even with framework alignment, individual devices still require pivotal trial data.
• Barrier Analysis:
  • Regulatory: EU member state variability may limit true harmonization
  • Infrastructure: Specialized TTVI centers needed regardless of regulatory pathway
  • Reimbursement: Device coverage remains fragmented across payers and countries
  • Industry: Small-company device developers may lack the resources to run parallel US/EU feasibility programs despite harmonized frameworks
  • Equity: Tricuspid disease is undertreated globally; regulatory convergence alone does not address access in LMICs

[CALL TO ACTION / CLOSING] The gap between a breakthrough device and a patient actually receiving it is often not scientific — it's regulatory. The work described here is the unglamorous but essential infrastructure of medical progress: making the rules clearer so that good devices can reach the people who need them faster.